Kidney Week

Abstract: TH-PO1025

Plasma Uromodulin Levels in Women with History of Preeclampsia and Association with Coronary Artery Calcification and Plasma Metabolome

Session Information

• Women's Health and Kidney Diseases
  November 06, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Women's Health and Kidney Diseases

• 2200 Women's Health and Kidney Diseases

Authors

• Dokic, Vladimir, Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States

Vladimir Dokic, MD, PhD

• Suvakov, Sonja, Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States

Sonja Suvakov, MD, PhD

• Jayachandran, Muthuvel, Mayo Clinic Department of Physiology and Biomedical Engineering, Rochester, Minnesota, United States

Muthuvel Jayachandran, PhD

• Vaughan, Lisa E., Mayo Clinic Department of Quantitative Health Sciences, Rochester, Minnesota, United States

Lisa E. Vaughan, MS

• Hatamova, Jennet, Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States

Jennet Hatamova

• Gavrilovici, Paul, Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States

Paul Gavrilovici

• Garcia Valencia, Oscar Alejandro, Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States

Oscar Alejandro Garcia Valencia, MD

• Garovic, Vesna D., Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States

Vesna D. Garovic, MD, PhD, FASN

Background

A history of preeclampsia (PE) increases the risk of coronary artery calcification (CAC), a precursor to cardiac events and stroke. Lower plasma uromodulin (pUMOD) is associated with a higher risk of cardiometabolic diseases in older adults. This study aimed to identify relationship between plasma metabolites, CAC and pUMOD in postmenopausal women with and without history of PE.

Methods

Plasma metabolites were analyzed by gas chromatography-mass spectrometry from postmenopausal women free of cardiovascular events with (n=30) and without (n=28) history of PE. CAC was measured by computer tomography, and pUMOD by ELISA. Metabolites were normalized with internal standard (myristic-d₂₇ acid) and results are expressed as relative amount. Comparisons between groups were conducted using the Wilcoxon rank sum test or Chi-square test, as appropriate.

Results

The body mass index, waist circumference, plasma lipids, current hypertension, insulin resistance, and CAC score (as previously reported) were greater in women with history of PE. pUMOD was lower in PE group, however, when stratified by CAC, pUMOD was significantly lower in PE+CAC group only. Several metabolites (proline, valine, isoleucine) were significantly or borderline (alpha ketoglutaric, malic and succinic acids, allothreonine) different in PE+CAC group compared to normotensive women with CAC. On the contrary, some metabolites (fumaric, glutamic and uric acids, alanine, methionine, pyrophosphate) differed between PE and normotensive women without CAC.

Conclusion

pUMOD is a biomarker of CAC in women with history of PE. PE history changes plasma metabolome in postmenopausal women which may contribute to development of CAC and cardiovascular events decades after pregnancy.

Funding

• NIDDK Support

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.2025ckzcjmfh